The company said it will release its financial results for Q4 2024 before the market opens on Thursday, February 6, 2025.

8-KRegulation FD DisclosureFiled Jan 8, 2025Period of report Jan 8, 2025Summary published (UTC) Oct 17, 2026

Key points

AI summary

The company said it will release its financial results for Q4 2024 before the market opens on Thursday, February 6, 2025.
It said it will hold a conference call and webcast at 9 a.m. ET that day to discuss the results, and that the earnings press release and related financial information will be posted on the Labcorp Investor Relations website.
The company said the webcast and dial-in are listen-only and recommended joining 10 minutes before the start. It said a replay will be available starting about 2 hours after the live event ends and until January 24, 2026.
The company said its boilerplate materials state that more than 67,000 employees support clients in approximately 100 countries, support for 84% of the new drugs and therapeutic products approved by the FDA in 2023, and more than 600 million tests performed.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Q4 2024 Earnings Release Schedule

The company said it will release its financial results for Q4 2024 before the market opens on Thursday, February 6, 2025.

Source · Based on the filing body and exhibits

Conference Call and Webcast Details

It said it will hold a conference call and webcast at 9 a.m. ET that day to discuss the results, and that the earnings press release and related financial information will be posted on the Labcorp Investor Relations website.

Source · Based on the filing body and exhibits

Webcast Access and Replay

The company said the webcast and dial-in are listen-only and recommended joining 10 minutes before the start. It said a replay will be available starting about 2 hours after the live event ends and until January 24, 2026.

Source · Based on the filing body and exhibits

Company Profile Figures

The company said its boilerplate materials state that more than 67,000 employees support clients in approximately 100 countries, support for 84% of the new drugs and therapeutic products approved by the FDA in 2023, and more than 600 million tests performed.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.